Arbutus Biopharma Corporation filed a Form 8-K on August 12, 2026, announcing the release of its financial results for the second quarter ended June 30, 2026.

Key Highlights

  • Filing date: August 12, 2026, covering the second quarter ended June 30, 2026.
  • Press release: A press release dated August 12, 2026, was furnished as Exhibit 99.1 and incorporated by reference.
  • Reporting period: Financial results are for Q2 2026, the three-month period ending June 30, 2026.
  • Signatory: The filing was signed by Tuan Nguyen, Chief Financial Officer of Arbutus Biopharma Corporation.
  • Exchange listing: Common Shares, without par value, are listed on The Nasdaq Stock Market LLC under the trading symbol ABUS.

Arbutus Biopharma Discloses Q2 2026 Results via Press Release

Arbutus Biopharma Corporation (NASDAQ:ABUS), a biopharmaceutical company incorporated in British Columbia, Canada, with principal executive offices at 701 Veterans Circle, Warminster, Pennsylvania 18974, filed a current report on August 12, 2026, under Item 2.02, Results of Operations and Financial Condition. According to the filing, the company issued a press release on that same date announcing its financial results for the second quarter ended June 30, 2026, along with "certain other information."

The press release, furnished as Exhibit 99.1, is incorporated by reference into the filing. The filing notes that the press release is furnished rather than filed, which is consistent with the Item 2.02 disclosure category. A Cover Page Interactive Data File, embedded within an Inline XBRL document, was also included as Exhibit 104, according to the filing.

The report was signed on behalf of the registrant by Tuan Nguyen, identified in the filing as Chief Financial Officer. The company holds Commission File Number 001-34949 and I.R.S. Employer Identification Number 98-0597776. The filing confirms that Arbutus Biopharma is not an emerging growth company as defined under applicable Securities Act and Exchange Act rules.

What Was Disclosed

Arbutus Biopharma filed an 8-K on August 12, 2026, to announce second-quarter 2026 financial results. The actual financial figures are contained in the attached press release, Exhibit 99.1, which is incorporated by reference but not reproduced in the body of the 8-K itself.